Memorial Sloan-Kettering Opens Rockefeller Outpatient Pavilion

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

NEW YORK-Memorial Sloan-Kettering Cancer Center’s new Laurance S. Rockefeller Outpatient Pavilion provides advanced programs for outpatient cancer diagnosis and treatment in a calm and beautiful environment. “We believe this facility will serve as a national model for the delivery of outpatient cancer care in the new millennium,” said Paul A. Marks, MD, president and CEO.

NEW YORK—Memorial Sloan-Kettering Cancer Center’s new Laurance S. Rockefeller Outpatient Pavilion provides advanced programs for outpatient cancer diagnosis and treatment in a calm and beautiful environment. “We believe this facility will serve as a national model for the delivery of outpatient cancer care in the new millennium,” said Paul A. Marks, MD, president and CEO.

The 190,000-square-foot facility is located at 53rd Street and Third Avenue in midtown Manhattan. Patient care services include gastrointestinal, genitourinary, gynecology (ovarian and cervical cancer); dermatology, thoracic oncology, clinical immunology, cardiology and pulmonary, radiology, and plastic and reconstructive surgery consultations, as well as pharmacy services, a boutique (see figure), and a conference center.

The physical environment is designed to convey a sense of peace and well-being, and includes several waterfalls, sculptural water gardens in 9 reception areas, and original works of art and poetry.

Other interesting aspects of the Rockefeller Pavilion include: organizing patient care services by specific diseases so that teams of specialists work together on the same floor; creating a technology infrastructure so that medical records and x-rays are tracked electronically and are easily available to members of the disease team; and providing patients with Internet access and a comprehensive patient education program with CD-ROMs.

Laurance S. Rockefeller, for whom the building is named, said: “This extraordinary new facility . . . stands as a symbol of our belief in the healing synergy between medical science and the power of each individual patient’s mind, body, and spirit.” Mr. Rockefeller is honorary co-chairman of the Boards of Overseers and Managers at Memorial Sloan-Kettering.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content